Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events.
Future Oncol
; 19(29): 2003-2012, 2023 Sep.
Article
en En
| MEDLINE
| ID: mdl-37449387
Lung cancer is a common disease and affects patients badly. Lorlatinib is a new and useful drug for this disease. But this drug has also some undesirable effects for the brain. These effects are generally mild and can be treated. This article discusses the undesirable effects of this drug on the brain and how to cope with these effects.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Future Oncol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Turquía